8CT Stock Chart & Stats
€0.33
€0.01(4.38%)
At close: 4:00 PM EDT
€0.33
€0.01(4.38%)
Day’s Range― - ―
52-Week Range€0.23 - €0.55
Previous CloseN/A
Volume0.00
Average Volume (3M)77.00
Market Cap
€29.34M
Enterprise Value€70.23
Total Cash (Recent Filing)€1.59M
Total Debt (Recent Filing)€160.06K
Price to Earnings (P/E)―
Beta-0.52
Next Earnings
Sep 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding122,842,766
10 Day Avg. Volume131
30 Day Avg. Volume77
Financial Highlights & Ratios
PEG Ratio-0.86
Price to Book (P/B)48.76
Price to Sales (P/S)0.00
P/FCF Ratio-50.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageLimited debt reduces interest and refinancing pressure compared with a highly leveraged structure. This gives Cannabix some financial flexibility to direct available resources toward research, product development, and commercialization, although it does not offset the company’s substantial losses and equity decline.
Cash Burn Tracks LossesCash consumption broadly matching reported losses suggests the company is not experiencing an additional, outsized working-capital drain beyond its operating deficit. If commercialization improves, this alignment could make future cash requirements more predictable, though funding needs remain significant.
Defined Technology FocusA focused product strategy around breath-based cannabis detection targets several related institutional applications rather than an undifferentiated consumer market. Shared breath-sampling hardware, analysis methods, and workflows could support a coherent platform as the company advances development.
Bears Say
Minimal Revenue BaseThe absence of meaningful revenue indicates that the business has not yet demonstrated commercial traction or recurring customer demand. This leaves future progress dependent on successful product development and adoption, while providing little internal funding for ongoing operations.
Persistent LossesWidening net losses alongside consistently negative gross profit show that current activity does not cover operating and product-related costs. Without a material improvement in revenue or cost absorption, continued losses can constrain investment capacity and weaken financial resilience.
Ongoing Cash BurnPersistent negative operating and free cash flow means the company cannot currently fund its activities from internally generated cash. Continued development therefore requires external funding or a future shift toward commercialization, creating ongoing pressure on capital resources.
Cannabix Technologies News
8CT FAQ
What was Cannabix Technologies Inc’s price range in the past 12 months?
Cannabix Technologies Inc lowest stock price was €0.23 and its highest was €0.55 in the past 12 months.
What is Cannabix Technologies Inc’s market cap?
Cannabix Technologies Inc’s market cap is €29.34M.
When is Cannabix Technologies Inc’s upcoming earnings report date?
Cannabix Technologies Inc’s upcoming earnings report date is Sep 29, 2026 which is tomorrow.
How were Cannabix Technologies Inc’s earnings last quarter?
Cannabix Technologies Inc released its earnings results on Mar 25, 2026. The company reported -€0.002 earnings per share for the quarter.
Is Cannabix Technologies Inc overvalued?
According to Wall Street analysts Cannabix Technologies Inc’s price is currently Overvalued.
Does Cannabix Technologies Inc pay dividends?
Cannabix Technologies Inc does not currently pay dividends.
What is Cannabix Technologies Inc’s EPS estimate?
Cannabix Technologies Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cannabix Technologies Inc have?
Cannabix Technologies Inc has 122,842,766 shares outstanding.
What happened to Cannabix Technologies Inc’s price movement after its last earnings report?
Cannabix Technologies Inc reported an EPS of -€0.002 in its last earnings report. Following the earnings report the stock price went up 11.726%.
Which hedge fund is a major shareholder of Cannabix Technologies Inc?
Currently, no hedge funds are holding shares in DE:8CT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cannabix Technologies Inc
Cannabix Technologies Inc., a technology company, develops marijuana and alcohol breathalyzer technologies for employers, law enforcement, workplaces, and laboratories in the United States. It offers Cannabix Marijuana Breath Test (MBT) for Tetrahydrocannabinol (THC) detection and quantification; Cannabix breath collection unit and breath cartridge for human breath sample collection, storage, and transportation. The company also provides BreathLogix alcohol breathalyzer, an autonomous alcohol screening system that enables screening of employees, contractors, and visitors in mining, construction, and oil and gas industries; and BreathLogix Connect (BLC), a cloud platform that is designed for streamlining data. It has a strategic partnership and development agreement with Omega Laboratories Inc. for the development and commercialization of the MBT technology. The company was formerly known as West Point Resources Inc. and changed its name to Cannabix Technologies Inc. in August 2014. Cannabix Technologies Inc. was incorporated in 2011 and is based in Burnaby, Canada.